Article

FDA approves AcuFocus corneal inlay

The FDA has approved AcuFocus’ corneal inlay product (KAMRA inlay.) The device is indicated to improve near vision by extending depth of focus in patients with presbyopia who have emmetropic refractions (+0.50 to –0.75 D).

The FDA has approved AcuFocus’ corneal inlay product (KAMRA inlay.) The device is indicated to improve near vision by extending depth of focus in patients with presbyopia who have emmetropic refractions (+0.50 to –0.75 D).

This approval represents the first major advancement in the surgical correction of presbyopia in more than a decade, according to company.

More from the show floor: Alcon receives FDA approval of new multifocal IOL

“The [inlay] is the number-one implanted corneal inlay globally,” said Jim Mazzo, chairman and chief executive officer of AcuFocus. “After a decade of research, development, and clinical investigation, we are delighted to bring this innovative technology to surgeons and patients in the United States.”

The approval was based on the results of 508 patients treated at 24 investigational sites worldwide. Patients in the clinical study experienced an average improvement in uncorrected near visual acuity of 3 lines between the åpreoperative exam and the 12-month follow-up visit. This improvement was maintained over the 5-year duration of the study.

Mean preoperative uncorrected distance visual acuity in the inlay-implanted eye was maintained across all follow-up exams.

The ultra-thin opaque ring measures 3.8 mm in total diameter, has a 1.6 mm central aperture, and is implanted monocularly into a patient’s non-dominant eye.

Next: more on the device

 

The device utilizes the principle of small-aperture optics, or pinhole effect, to extend depth-of-focus for patients suffering from age-related near vision loss. Central-focused light is allowed to reach the retina uninterrupted resulting in functional vision from near to far without reading glasses.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
© 2025 MJH Life Sciences

All rights reserved.